Stephanie Braillard

Geneve, GE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Population pharmacokinetics of DNDI-6148 in healthy adults.

Population pharmacokinetics of DNDI-6148 in healthy adults.

Journal: PLoS neglected tropical diseases

Published: November 03, 2025

Safety, tolerability and pharmacokinetics of DNDI-6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants.

Safety, tolerability and pharmacokinetics of DNDI-6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants.

Journal: British journal of clinical pharmacology

Published: April 04, 2025

DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1.

DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1.

Journal: Science translational medicine

Published: December 13, 2023

Short-course combination treatment for experimental chronic Chagas disease.

Short-course combination treatment for experimental chronic Chagas disease.

Journal: Science translational medicine

Published: December 13, 2023

DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.

DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.

Journal: Journal of medicinal chemistry

Published: October 29, 2021

Identification of Resistance Determinants for a Promising Antileishmanial Oxaborole Series.

Identification of Resistance Determinants for a Promising Antileishmanial Oxaborole Series.

Journal: Microorganisms

Published: April 20, 2021

Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis.

Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis.

Journal: Pharmaceutics

Published: February 26, 2021

Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility.

Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility.

Journal: ACS medicinal chemistry letters

Published: December 12, 2020

Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.

Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.

Journal: European journal of medicinal chemistry

Published: July 15, 2020

Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance.

Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance.

Journal: Antimicrobial agents and chemotherapy

Published: January 21, 2020

Development and validation of LC-MS/MS method for determination of DNDI-VL-2098 in mouse, rat, dog and hamster blood.

Development and validation of LC-MS/MS method for determination of DNDI-VL-2098 in mouse, rat, dog and hamster blood.

Journal: Bioanalysis

Published: September 07, 2019

Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis.

Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis.

Journal: Antimicrobial agents and chemotherapy

Published: April 17, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026